Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors

Cardiovascular Drug Reviews

Volumn 24, Issue 2, 2006, Pages 169-188

  Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

CYP450 metabolites; Epoxide hydrolase; Epoxyeicosatrienoic acids; Hypertension; Inflammation; Nephropathy; Stroke

Indexed keywords

1 CYCLOHEXYL 3 DODECYL UREA; 12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; 4 PHENYLCHALCONE OXIDE; CYCLOOXYGENASE 2 INHIBITOR; EPOXIDE HYDROLASE INHIBITOR; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; ENZYME INHIBITOR; EPOXIDE HYDROLASE;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; HUMAN; KIDNEY INJURY; LEUKOCYTE MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASODILATATION; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; PATHOPHYSIOLOGY; SOLUBILITY;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; SOLUBILITY; VASODILATION;

EID: 34247867952     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00169.x     Document Type: Review

References (124)

1. Abraham G, Simon G. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am J Hypertens 1994 7 : 269 275.
2. Alkayed NJ, Birks EK, Narayanan J, Petrie KA, Kohler-Cabot AE, Harder DR. Role of P-450 arachidonic acid epoxygenase in the response of cerebral blood flow to glutamate in rats. Stroke 1997 28 : 1066 1072.
3. Anderson WP, Kett MM, Stevenson KM, Edgley AJ, Denton KM, Fitzgerald SM. Renovascular hypertension: Structural changes in the renal vasculature. Hypertension 2000 36 : 648 652.
4. Argiriadi MA, Morisseau C, Hammock BD, Christianson DW. Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolase. Proc Natl Acad Sci USA 1999 96 : 10637 10642.
5. Argiriadi MA, Morisseau C, Goodrow MH, Dowdy DL, Hammock BD, Christianson DW. Binding of alkyl-urea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J Biol Chem 2000 275 : 15265 15270.
6. Beetham JK, Tian T, Hammock BD. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch Biochem Biophys 1993 305 : 197 201.
7. Beetham JK, Grant D, Arand M, et al. Gene evolution of epoxide hydrolases and recommended nomenclature. DNA Cell Biol 1995 14 : 61 71.
8. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996 78 : 415 423.
9. Chacos N, Capdevila J, Falck JR, et al. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 1983 223 : 639 648.
10. Cowley AW, Roman RJ. The role of the kidney in hypertension. JAMA 1996 275 : 1581 1589.
11. Cronin A, Mowbray S, Durk H, et al. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci USA 2003 100 : 1552 1557.
12. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2002 99 : 2222 2227.
13. Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3- dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther 2006 316 : 815 821.
14. Dietze EC, Kuwano E, Casas J, Hammock BD. Inhibition of cytosolic epoxide hydrolase by trans-3-phenyl-glycidols. Biochem Pharmacol 1991 42 : 1163 1175.
15. Dobesh PP. Managing hypertension in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2006 63 : 1140 1149.
16. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005 46 : 842 848.
17. Dreisbach AW, Japa S, Sigel A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005 18 : 1276 1281.
18. Enayetallah AE, Grant DF. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem Biophys Res Commun 2006 341 : 254 260.
19. Falck JR, Reddy LM, Reddy YK, et al. 11,12-epoxyeicosatrienoicacid(11,12- EET): Structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett 2003 13 : 4011 4014.
20. Falck JR, Krishna UM, Reddy YK, et al. Comparison of vasodilatory properties of 14,15-EET analogs: Structural requirements for dilation. Am J Physiol Heart Circ Physiol 2003 284 : H337 349.
21. Fang X, Moore SA, Stoll LL, et al. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol 1998 275 : H2113 2121.
22. Fang X, Kaduce TL, VanRollins M, Weintraub NL, Spector AA. Conversion of epoxyeicosatrienoic acids (EETs) to chain-shortened epoxy fatty acids by human skin fibroblasts. J Lipid Res 2000 41 : 66 74.
23. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001 276 : 14867 14874.
24. Fang X, Weintraub NL, Oltman, CL, et al. Human coronary endothelial cells convert 14,15-EETto a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol 2002 283 : H2306 2314.
25. Fang X, Weintraub NL, McCaw RB, et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 2004 287 : H2412 2420.
26. Fang X, Hu S, Watanabe T, et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 2005 314 : 260 270.
27. Fang X, Hu S, Xu B, et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am J Physiol Heart Circ Physiol 2006 290 : H55 63.
28. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999 401 : 493 497.
29. Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10,11-epoxide by quetiapine. Phamacotherapy 2002 22 : 1500 1503.
30. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, Liggett WF. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 1986 261 : 15334 15338.
31. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, Busse R. The coronary endothelium-derived hyper-polarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflügers Arch 2001 442 : 511 518.
32. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001 89 : 753 762.
33. Fleming I, Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 2006 47 : 629 633.
34. Fornage M, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 2002 40 : 485 490.
35. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004 109 : 335 339.
36. Fornage M, Lee CR, Doris PA, et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005 14 : 2829 2837.
37. Fujii K, Weno BL, Baumbach GL, Heistad DD. Effect of antihypertensive treatment on focal cerebral infarction. Hypertension 1992 19 : 713 716.
38. Gauthier KM, Falck JR, Reddy LM, Campbell WB. 14,15-EET analogs: Characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res 2004 49 : 515 524.
39. Hammock BD, Ratcliff M, Schooley DA. Hydration of an 18O epoxide by a cytosolic epoxide hydrolase from mouse liver. Life Sci 1980 27 : 1635 1641.
40. Heizer ML, McKinney JS, Ellis EF. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 1991 22 : 1389 1393.
41. Hoebel BG, Graier WF. 11,12-Epoxyeicosatrienoic acid stimulates tyrosine kinase activity in porcine aortic endothelial cells. Eur J Pharmacol 1998 346 : 115 117.
42. Iber H, Chen Q, Cheng PY, Morgan ET. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 2000 377 : 187 194.
43. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996 7 : 2364 2370.
44. Imig JD. Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am J Hypertens 2000 13 : 810 818.
45. Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 2000 35 : 307 312.
46. Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens 2001 19 : 983 992.
47. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002 39 : 690 694.
48. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005 289 : F496 503.
49. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005 46 : 975 981.
50. Ito T, Yamakawa H, Brefonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angio-tensin II AT1 antagonist. Stroke 2002 33 : 2297 2303.
51. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005 45 : 759 765.
52. Kessler P, Popp R, Busse R, Schini-Kerth VB. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-de-pendent mechanism. Circulation 1999 99 : 1878 1884.
53. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999 19 : 511 532.
54. Kim IH, Morisseau C, Watanabe T, Hammock BD. Design, synthesis, and biological activity of 1,3-disubsti-tuted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004 47 : 2110 2122.
55. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 2005 48 : 3621 3629.
56. Kozak W, Kluger MJ, Kozak A, Wachulec M, Dokladny K. Role of cytochrome P-450 in endogenous anti-pyresis. Am J Physiol Regul Integr Comp Physiol 2000 279 : R455 460.
57. Krotz F, Riexinger T, Buerkle MA, et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 2004 24 : 595 600.
58. Larsen BT, Miura H, Hatoum OA, et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 2006 290 : H491 499.
59. Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006 15 : 1640 1649.
60. Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow: The role of PPARä, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005 102 : 16747 16752.
61. Lu Q, Zhu YZ, Wong PT. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005 16 : 1963 1967.
62. Ma YH, Schwartzman ML, Roman RJ. Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol 1994 267 : R579 589.
63. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994 94 : 2414 2420.
64. Matsuda H, Hayashi K, Wakino S, et al. Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 2004 43 : 603 609.
65. Medhora M, Daniels J, Mundey K, et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 2003 284 : H215 224.
66. Miyoshi A, Suzuki H, Fujiwara M, Masai M, Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am J Hypertens 1997 10 : 1083 1090.
67. Morgan ET, Ullrich V, Daiber A, et al. Cytochromes P450 and flavin monooxygenases - targets and sources of nitric oxide. Drug Metab Dispos 2001 29 : 1366 1376.
68. Morisseau C, Du G, Newman JW, Hammock BD. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Arch Biochem Biophys 1998 356 : 214 228.
69. Morisseau C, Goodrow MH, Dowdy D, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 1999 96 : 8849 8854.
70. Morisseau C, Beetham JK, Pinot F, Debernard S, Newman JW, Hammock BD. Cress and potato soluble epoxide hydrolases: Purification, biochemical characterization, and comparison to mammalian enzymes. Arch Biochem Biophys 2000 378 : 321 332.
71. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002 63 : 1599 1608.
72. Morisseau C, Hammock BD. Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005 45 : 311 333.
73. Mullin CA, Hammock BD. Chalcone oxides - potent selective inhibitors of cytosolic epoxide hydrolase. Arch Biochem Biophys 1982 216 : 423 439.
74. Munzenmaier DH, Harder DR. Cerebral microvascular endothelial cell tube formation: Role of astrocytic epoxyeicosatrienoic acid release. Am JPhysiol Heart Circ Physiol 2000 278 : H1163 1167.
75. Newman JW, Morisseau C, Harris TR, Hammock BD. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 2003 100 : 1558 1563.
76. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 2005 44 : 1 51.
77. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000 31 : 2478 2486.
78. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999 285 : 1276 1279.
79. Node K, Ruan XL, Dai J, et al. Activation of Gás mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 2001 276 : 15983 15989.
80. Nourooz-Zadeh J, Uematsu T, Borhan B, Kurth MJ, Hammock BD. Characterization of the cytosolic epoxide hydrolase-catalyzed hydration products from 9,10:12,13-diepoxy stearic esters. Arch Biochem Biophys 1992 294 : 675 685.
81. Oesch F, Jerina DM, Daly JW, Rice JM. Induction, activation and inhibition of epoxide hydrase: An anomalous prevention of chlorobenzene-induced hepatotoxicity by an inhibitor of epoxide hydrase. Chem Biol Interact 1973 6 : 189 202.
82. Oesch F, Schladt L, Hartmann R, Timms C, Worner W. Rat cytosolic epoxide hydrolase. Adv Exp Med Biol 1986 197 : 195 201.
83. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantly-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther 2006 E-pub ahead of print PMID16772540.
84. Olearczyk JJ, Kim IH, Hammock BD, Imig JD. Inhibition of epoxide hydrolase decreases the expression of pro-inflammatory genes in hypertensive Goto-Kakizaki rats. Hypertension 2005 46 : 856.
85. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosa-trienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998 83 : 932 939.
86. Pokreisz P, Fleming I, Kiss L, et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006 47 : 762 770.
87. Pomposiello SI, Alva M, Wilde DW, Carretero OA. Linoleic acid induces relaxation and hyperpolarization of the pig coronary artery. Hypertension 1998 31 : 615 620.
88. Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC. 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension 2003 42 : 548 554.
89. Potente M, Michaelis UR, Fisslthaler B, Busse R, Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 2002 277 : 15671 15676.
90. Potente M, Fisslthaler B, Busse R, Fleming I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27kip1. J Biol Chem 2003 278 : 29619 29625.
91. Pozzi A, Macias-Perez I, Abair T, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005 280 : 27138 27146.
92. Pratt PF, Rosolowsky M, Campbell WB. Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. Life Sci 2002 70 : 2521 2533.
93. Proctor KG, Falck JR, Capdevila J. Intestinal vasodilation by epoxyeicosatrienoic acids: Arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. Circ Res 1987 60 : 50 59.
94. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, et al. Polymorphisms in human soluble epoxide hydrolase. MolPharmacol 2003 64 : 482 490.
95. Reddy SR, Kotchen TA. Attenuation of experimental hypertension by dietary linoleic acid is model dependent. J Am Coll Nutr 1996 15 : 92 96.
96. Sato K, Emi M, Ezura Y, et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: Intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 2004 49 : 29 34.
97. Schmelzer K, Inceoglu B, Kubala L, Kim IH, Eiserich J, Hammock BD. Novel therapy for acute inflammation: Co-administration of non-steroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitor. FASEB J 2006 20 : A1129.
98. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl AcadSci USA 2005 102 : 9772 9777.
99. Sellers KW, Sun C, Diez-Freire C, et al. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J 2005 19 : 626 628.
100. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004 95 : 506 514.
101. Seubert JM, Xu F, Graves JP, et al. Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats. Am J Physiol Renal Physiol 2005 289 : F552 561.
102. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000 275 : 40504 40510.
103. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005 102 : 2186 2191.
104. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog Lipid Res 2004 43 : 55 90.
105. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005 433 : 413 420.
106. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 2002 90 : 1020 1027.
107. Van Rollins M, Kaduce TL, Knapp HR, Spector AA. 14,15-Epoxyeicosatrienoic acid metabolism in endothelial cells. J Lipid Res 1993 34 : 1931 1942.
108. Waechter F, Bentley P, Bieri F, Staubli W, Volkl A, Fahimi HD. Epoxide hydrolase activity in isolated per-oxisomes of mouse liver. FEBS Lett 1983 158 : 225 228.
109. Wang P, Meijer J, and Guengerich FP. Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme. Biochemistry 1982 21 : 5769 5776.
110. Wang Y, Wei X, Xiao X, et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 2005 314 : 522 532.
111. Watanabe T, Morisseau C, Newman JW, Hammock BD. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos 2003 31 : 846 853.
112. Wei Q, Doris PA, Pollizotto MV, et al. Sequence variation in the soluble epoxide hydrolase gene and subcli-nical coronary atherosclerosis: Interaction with cigarette smoking. Atherosclerosis 2006 E-pub ahead of print PMID16545818.
113. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol 1999 277 : H2098 2108.
114. Yang B, Graham L, Dikalov S, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001 60 : 310 320.
115. Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: Influence of temperature and time. Ann Thorac Surg 2003 76 : 1623 1630.
116. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004 351 : 1106 1118.
117. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000 87 : 992 998.
118. Yu Z, Davis BB, Morisseau C, et al. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 2004 286 : F720 726.
119. Zhang C, Harder DR. Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 2002 33 : 2957 2964.
120. Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15- epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 2006 281 : 905 914.
121. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension 2003 41 : 709 714.
122. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004 15 : 1244 1253.
123. Zheng J, Plopper CG, Lakritz J, Storms DH, Hammock BD. Leukotoxindiol: A putative toxic mediator involved in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2001 25 : 434 438.
124. Zou AP, Fleming JT, Falck JR, et al. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K+-channel activity. Am J Physiol 1996 270 : F822 832.